Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers

The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine

(2012) Ghassan Dbaibo et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Measurement of Functional Anti-Meningococcal Serogroup A Activity Using Strain 3125 as the Target Strain for Serum Bactericidal Assay

(2011) Jan T. Poolman et al.   Clinical and Vaccine Immunology

Changing epidemiology of meningococcal disease in Europe from the mid-20th to the early 21st Century

(2011) Paula Kriz et al.   Expert Review of Vaccines

Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents

(2011) Christopher J. Gill et al.   Human vaccines & immunotherapeutics

Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults

(2011) Nancy Bermal et al.   Human vaccines & immunotherapeutics

Immunogenicity of a Single Dose of Tetravalent Meningococcal Serogroups A, C, W-135, and Y Conjugate Vaccine Administered to 2- to 10-year-olds Is Noninferior to a Licensed-ACWY Polysaccharide Vaccine With an Acceptable Safety Profile

(2011) Ziad A. Memish et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal ACWY Tetanus Toxoid Conjugate Vaccine in Healthy Adolescents and Young Adults 10 to 25 Years of Age

(2011) Roger Baxter et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Emergence of Epidemic Neisseria meningitidis Serogroup X Meningitis in Togo and Burkina Faso

(2011) Isabelle Delrieu et al.   PLoS One

An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12–23-month-old children

(2011) Markus Knuf et al.   VACCINE

Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles–mumps–rubella–varicella vaccine during the second year of life: An open, randomized controlled trial

(2011) Timo Vesikari et al.   VACCINE

Updated Postlicensure Surveillance of the Meningococcal C Conjugate Vaccine in England and Wales: Effectiveness, Validation of Serological Correlates of Protection, and Modeling Predictions of the Duration of Herd Immunity

(2010) H. Campbell et al.   Clinical and Vaccine Immunology

Optimizing Protection Against Meningococcal Disease

(2010) Keith S. Reisinger et al.   CLINICAL PEDIATRICS

ANTIBODY PERSISTENCE 12 MONTHS AFTER A BOOSTER DOSE OF MENINGOCOCCAL-C CONJUGATED VACCINE IN THE SECOND YEAR OF LIFE

(2010) Javier Diez-Domingo et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

A Randomized, Multicenter, Open-Label Clinical Trial to Assess the Immunogenicity of a Meningococcal C Vaccine Booster Dose Administered to Children Aged 14 to 18 Months

(2010) Javier Díez-Domingo et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity and Safety of an Investigational Combined Haemophilus influenzae Type B-Neisseria meningitidis Serogroups C and Y-Tetanus Toxoid Conjugate Vaccine

(2010) Terry Nolan et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Long-term Sequelae of Childhood Bacterial Meningitis

(2010) Aruna Chandran et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunity against Neisseria meningitidis Serogroup C in the Dutch Population before and after Introduction of the Meningococcal C Conjugate Vaccine

(2010) Richarda M. de Voer et al.   PLoS One

Ex Vivo Model of Meningococcal Bacteremia Using Human Blood for Measuring Vaccine-Induced Serum Passive Protective Activity

(2009) J. S. Plested et al.   Clinical and Vaccine Immunology

Kinetics of Antibody Persistence following Administration of a Combination Meningococcal Serogroup C and Haemophilus influenzae Type b Conjugate Vaccine in Healthy Infants in the United Kingdom Primed with a Monovalent Meningococcal Serogroup C Vaccine

(2009) R. Borrow et al.   Clinical and Vaccine Immunology

Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers

(2009) S. A. Halperin et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

A Randomized Trial to Determine the Tolerability and Immunogenicity of a Quadrivalent Meningococcal Glycoconjugate Vaccine in Healthy Adolescents

(2009) Lisa A. Jackson et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Randomized Trial to Assess Immunogenicity and Safety of Haemophilus influenzae Type b and Neisseria meningitidis Serogroups C and Y–Tetanus Toxoid Conjugate Vaccine in Infants

(2009) Colin D. Marchant et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Quadrivalent meningococcal conjugate vaccines

(2009) David Pace et al.   VACCINE

Global epidemiology of meningococcal disease

(2009) Lee H. Harrison et al.   VACCINE

A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children

(2009) M. Knuf et al.   VACCINE

Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2–10 years of age

(2009) S. Black et al.   VACCINE

Binding of Complement Factor H (fH) to Neisseria meningitidis Is Specific for Human fH and Inhibits Complement Activation by Rat and Rabbit Sera

(2008) D. M. Granoff et al.   INFECTION AND IMMUNITY

Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25 years

(2008) Lars Østergaard et al.   VACCINE